Achilles Therapeutics (ACHL)
1.16
0.00 (0.00%)
At close: Jan 14, 2025, 3:59 PM
1.17
0.86%
After-hours Jan 14, 2025, 03:59 PM EST
undefined% (undefined)
| Bid | 1.11 |
| Market Cap | 47.68M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.66 |
| PE Ratio (ttm) | -0.7 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 1.19 |
| Volume | 50,863 |
| Avg. Volume (20D) | 172,852 |
| Open | 1.16 |
| Previous Close | 1.16 |
| Day's Range | 1.13 - 1.17 |
| 52-Week Range | 0.63 - 1.76 |
| Beta | undefined |
About ACHL
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also dev...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 31, 2021
Employees 204
Stock Exchange NASDAQ
Ticker Symbol ACHL
Website https://www.achillestx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for ACHL stock is "Hold." The 12-month stock price forecast is $4, which is an increase of 244.83% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
3 months ago ·
Source
+32.39%
Achilles Therapeutics shares are trading higher. T...
Unlock content with
Pro Subscription
9 months ago ·
Source
-24.76%
Achilles Therapeutics shares are trading lower after the company reported Q4 financial results. The company announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer and the THETIS study in recurrent or metastatic malignant melanoma.
